I guess we would exect it to be positive but the four points...

I guess we would exect it to be positive but the four points that grabbed me :-

i) Self funding by end this fin year (June 2012) with 4-6 million revenue for this (second) half.
ii) expect revenue to double in 12/13 (so 8 - 12 mill ?)
Again the magic number of 3 new deals and second bites for current relationships.
iii) Co-investing concept implies they are getting more positive/confident about the end game for some of these peptides ie. research is going well for at least some of the current programmes. Does that mean they are abandoning the concept of flogging the whole box and dice for now ?
iv) Roche relationship currently alive and well contrasts with adverse speculation on this board.

Hopefully it all comes to pass. If it does we see a re-rating here I expect. At least it is not long to wait to see if Nick has it (almost) right this time.